 
Marksans Pharma Ltd. 
11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, 
Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000  
E-mail: companysecretary@marksanspharma.com 
www.marksanspharma.com 
 
 
 
November 20, 2025 
 
 
BSE Limited      National Stock Exchange of India Limited 
Corporate Relation Department   Listing Department 
Phiroze Jeejeebhoy Towers   Exchange Plaza, C-1, Block - G 
Dalal Street     Bandra-Kurla Complex 
Mumbai – 400001    Bandra (East), Mumbai - 400051 
Scrip Code: 524404    Symbol: MARKSANS 
 
 
 
Sub: Press Release 
 
Marksans Pharma Limited’s wholly owned subsidiary in UK, Relonchem Limited receives 
Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution. 
 
 
Marksans Pharma Limited (Reuters: MARK.BO; Bloomberg: MRKS IN; NSE: MARKSANS; BSE: 
524404) hereby announces that its wholly owned subsidiary Relonchem Limited in UK has received 
Marketing Authorization for its product Cetirizine Dihydrochloride 1 mg/ml Oral Solution  from UK 
MHRA. 
 
Please take the above information on record. 
 
Thanking you. 
 
Yours faithfully 
For Marksans Pharma Limited 
 
 
 
 
 
Harshavardhan Panigrahi  
Company Secretary 
 
 
 
About Marksans Pharma Ltd 
Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is 
engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in 
the global markets. The company's manufacturing facilities located in India, USA and UK are 
approved by several leading regulatory agencies including USFDA, UKMHRA and 
Australian TGA. The Company's robust product portfolio spreads over major therapeutic 
segments of CVS, CNS, Anti-diabetic, Pain Management, Gastroenterological, Anti-allergies, 
Upper respiratory, Oncology, Anti -biotic, etc . The Company is marketing these products 
globally. 
